Boehringer to sell stake in Hikma
Boehringer’s stake in the firm equates to around 16.4%
Read More
Tag: Boehringer
Boehringer to launch first reusable soft mist inhaler
Pharmacists are likely to see people with COPD and asthma more regularly than a GP or nurse, so they play a pivotal role in educating patients on their medicines and inhaler technique.
Read More
Boehringer expands IPF pipeline with addition of BBT-877
Under the terms of the deal Bridge Biotherapeutics will receive upfront and near term payments of 45 million Euros and is eligible to receive up to more than 1.1 billion Euros in potential payments.
Read More
Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition
AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
Read More
Boehringer buys ViraTherapeutics
Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics.
Read More
Boehringer’s Spiriva gets UK license for young asthma patients
Boehringer Ingelheim’s Spiriva Respimat is now licensed for use in the UK to treat people with asthma aged six years and older.
Read More
Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.
Read More
BI snaps up OSE’s novel checkpoint inhibitor
Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.
Read More
BI, Lilly expand Jardiance programme in heart failure
Boehringer Ingelheim and Eli Lilly are expanding their clinical trial programme for Jardiance in chronic heart failure (CHF) with two new Phase III studies.
Read More
Boehringer ends development of Alzheimer’s candidate
Boehringer Ingelheim is ending development of BI 409306 in Alzheimer’s disease on disappointing mid-stage trial data.
Read More
PIM status for Boehringer’s mesothelioma drug
Boehringer Ingelheim’s nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency.
Read More
Boehringer Ingelheim signs Evox, Roche deals
Boehringer Ingelheim signs new deals with UK-based Evox Technologies and Roche.
Read More
- US study reveals interferon combinations cause lupus symptoms and affect treatment
- NIHR and TJBCM announce new funding initiative for novel brain tumour research
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
